Business methodology

Sales are generated mainly from the lead product Zubsolv® for the treatment of opioid use disorder. Other revenues come from out-licensing of Zubsolv or other drugs commercialized by partners, such as Abstral® for breakthrough cancer pain and Edluar® for insomnia. Revenues from the lead product have enabled investments in research and development as well as in digital mental health programs. Investments in these assets are expected to generate future revenues from sales, including upfront and milestone payments, and royalty. 

• Commercialization of pharmaceuticals and digital mental health programs in the US
• Product out-licensing
• Co-development
• Supply chain

Orexo develops pharmaceuticals meeting large medical needs and that are based on proprietary drug delivery technologies. Cross-functional teams bring together competencies in research and development, medical affairs, and business development to evaluate potential future projects. Orexo’s long experience in developing pharmaceuticals that have reached approval in markets globally has brought extensive knowledge throughout the entire development chain. Central to the development process is building a strong patent portfolio that covers all products and development projects.

• Preclinical and clinical development
• Supply chain
• Regulatory Affairs
• Intellectual properties
• Partnering

The presence on the American market provides the opportunity to have regular interactions with authorities, decisionmakers, healthcare systems, insurance companies and patient organizations. In addition to pushing for decisions to be made that increase access to treatment, these interactions provide unique knowledge that is used, among other things, in the evaluation of new development projects. The sales force meets daily with private practitioners, clinics and hospitals and is an important distribution channel for reaching out with treatments to those who need them most.

• Stakeholder engagement and advocacy
• Pricing and reimbursement
• Sales and marketing
• Phase IV and RWE clinical trials